Income statement
USD
Annual
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 12K | 12K | 4K | 0 |
| Gross Profit | 12K | 12K | 4K | 0 |
| Operating Income | -149K | -56K | -88K | -46K |
| EBITDA | -142K | 119K | -88K | 0 |
| Net Income | -180K | -245K | -102K | -46K |
| EPS (Diluted) | — | — | — | — |
Healthcare
Live Price
Offline$0.055
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 252 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SYBLEU Inc (SYBE) is a Healthcare stock with listed on OTC. The stock last traded around $0.06 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of -0.0%, EPS growth of +24.2%, a dividend yield of 0.0%. What stands out right now is revenue -0.0%, EPS +24.2%, free cash flow -28.1% with operating margin -1275.5% and ROIC -502.0%. Valuation already assumes a fairly strong business story at price/sales 49.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SYBE price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SYBE
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SYBE Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SYBE and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$46.3K
+54.5% YoY
Free Cash Flow
-$75.3K
+14.7% YoY
Revenue Growth
-0.0%
EPS Growth
+24.2%
Gross Margin
100.0%
Net Margin
-1541.6%
Income statement
USD
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 12K | 12K | 4K | 0 |
| Gross Profit | 12K | 12K | 4K | 0 |
| Operating Income | -149K | -56K | -88K | -46K |
| EBITDA | -142K | 119K | -88K | 0 |
| Net Income | -180K | -245K | -102K | -46K |
| EPS (Diluted) | — | — | — | — |
Balance sheet
USD
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Cash & Equivalents | 37K | 67K | 14K | 5K |
| Total Assets | 61K | 76K | 200K | 9K |
| Total Liabilities | 327K | 326K | 204K | 11K |
| Shareholder Equity | -266K | -250K | -5K | -3K |
| Total Debt | 140K | 140K | 9K | 11K |
| Net Debt | 103K | 73K | -5K | 6K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
75K
+14.7% YoY
Capital Expenditures
0
Free Cash Flow
75K
+14.7% YoY
Key ratios
Gross Margin
100.0%
Operating Margin
-1275.5%
Net Margin
-1541.6%
ROE
69.9%
Debt / Equity
-0.53x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.